Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 2/20 | 0.62 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.53 |
| ▸ | KCNA5 known ✓ | P22460 | 2/20 | 0.53 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.52 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.52 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.52 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.52 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.52 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.52 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1167925 | 1.00 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL18185314 | 1.00 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL2123774 | 0.99 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL30852356 | 0.99 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL16007455 | 0.99 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL1167928 | 0.99 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL31258991 | 0.99 | TACR1 (0.64) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL5391034 | 0.95 | TACR1 (0.60) | TACR1MAPTKDM4EMEN1LMNA | |
| Hydrochloric Acid SCHEMBL5391037 | 0.95 | TACR1 (0.60) | TACR1MAPTKDM4EMEN1LMNA | |
| SCHEMBL6423830 | 0.95 | TACR1 (0.62) | TACR1MAPTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9175006-B2 | Compositions and methods for cyclofructans as separation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-02-03 | — | — | US | disclosed |
| US-7163671-B2 | Long-term stabilized formulations | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-16 | — | — | US | disclosed |
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-20030092622-A1 | Preparation stabilized over long time | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1260230-A1 | PREPARATIONS STABILIZED OVER LONG TIME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5712289-A | ANTITUMOR AGENTS, INTERMEDIATES FOR LAVENDAMYCINS | BALL STATE UNIVERSITY (US) | 1998-01-27 | — | — | US | disclosed |
| US-5646150-A | ADMINISTERING AS ANTITUMOR AGENT, ANTIPROTOZOA AGENT, VIRICIDE, PARASITICIDE, OR BACTERICIDE | BALL STATE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5525611-A | ANTITUMOR AGENT, BACTERICIDES, VIRICIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1996-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | PAICS, DCXR, PFAS | TACR1 869/4885SCN9A 4648/4885HTR2A 3787/4885 |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | TACR1 4381/4885SCN9A 3512/4885HTR2A 2970/4885 |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | TACR1 337/4885SCN9A 3277/4885HTR2A 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.